Zoetis Inc. announced Tuesday a deal to buy veterinary diagnostics company Abaxis Inc. in a deal valued at $2.0 billion. Abaxis shares are currently halted, and are scheduled to resume trade at 7:30 a.m. ET. Under terms of the deal, Zoetis will pay $83 in cash for each Abaxis share outstanding, which is 15.7% above Monday’s closing price and would give Abaxis a market capitalization of about $1.88 billion. Zoetis said the deal, which is to close by the end of 2018, will add to earnings in 2019. “This acquisition brings Zoetis a company that has a proven, competitive diagnostic platform for growth that we can help to accelerate in the U.S. and worldwide with our global scale and direct customer relationships in approximately 45 countries,” said Zoetis Chief Executive Juan Ramon Alaix. Abaxis’s stock has soared 44.9% year to date, while Zoetis shares have climbed 15.2% and the S&P 500 has gained 1.4%.